Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia
- Resource Type
- Authors
- Brenda Gibson; Karen Keeshan; Ashley Newcombe
- Source
- Experimental hematology. 63
- Subject
- 0301 basic medicine
Cancer Research
Myeloid
Oncogene Proteins, Fusion
Antineoplastic Agents
Bioinformatics
Translocation, Genetic
Epigenesis, Genetic
03 medical and health sciences
0302 clinical medicine
hemic and lymphatic diseases
Genetics
medicine
Neoplasm
Humans
Epigenetics
Enzyme Inhibitors
Child
neoplasms
Molecular Biology
Epigenesis
Clinical Trials as Topic
business.industry
Gene Expression Regulation, Leukemic
Childhood Acute Myeloid Leukemia
Myeloid leukemia
Cell Biology
Hematology
Genetic Therapy
DNA Methylation
medicine.disease
Combined Modality Therapy
Hematopoiesis
Histone Code
Histone Deacetylase Inhibitors
Leukemia
Leukemia, Myeloid, Acute
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
Mutation
Immunotherapy
business
Epigenetic therapy
Genes, Neoplasm
Signal Transduction
- Language
- ISSN
- 1873-2399
There is a desperate need for new and effective therapeutic approaches to acute myeloid leukemia (AML) in both children and adults. Epigenetic aberrations are common in adult AML, and many novel epigenetic compounds that may improve patient outcomes are in clinical development. Mutations in epigenetic regulators occur less frequently in AML in children than in adults. Investigating the potential benefits of epigenetic therapy in pediatric AML is an important issue and is discussed in this review.